Orthobiologic Therapies for Musculoskeletal Injuries and Healing

Regenerative Medicine: Navigating Orthobiologic Therapies for Musculoskeletal Injuries

Abstract

Hello, I’m Dr. Alex Jimenez. As a Doctor of Chiropractic, Advanced Practice Registered Nurse, and board-certified Family Nurse Practitioner with extensive training in functional and regenerative medicine, my mission is to integrate the best of multiple disciplines to achieve superior patient outcomes. This post explores the evidence-based application of orthobiologic therapies, such as Platelet-Rich Plasma (PRP) and microfragmented adipose tissue (MFAT), for a range of musculoskeletal conditions. We will explore the specific indications for these treatments, from partial-thickness rotator cuff tears to osteoarthritis, and examine the physiological rationale behind their use. I’ll share my clinical thought process, supported by the latest research, including a groundbreaking machine-learning study that helps predict patient response to PRP. Furthermore, I am proud to announce a significant enhancement to our practice. Dr. Maria Guadalupe Cardenas, MD, a highly respected internist with over 40 years of experience, has joined our team at Injury Medical Clinic PA as our Medical Director and Collaborative Physician. This collaboration formalizes our multidisciplinary approach, blending chiropractic care, functional medicine, and advanced medical oversight to provide comprehensive, patient-centered care for complex injuries and chronic conditions.

A New Era of Integrated Care at Injury Medical Clinic

I am thrilled to share some wonderful news for our community here in El Paso, Texas. Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933), has officially joined our practice, Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic), as our Medical Director and Collaborative Physician. Dr. Cardenas is a board-certified internist with an incredible four decades of experience. Her wisdom, clinical acumen, and deep understanding of internal medicine bring an invaluable dimension to our patient care model.

This collaboration establishes a truly integrative, multidisciplinary environment. My role, focusing on advanced chiropractic techniques, functional medicine diagnostics, and rehabilitation, is now synergistically paired with Dr. Cardenas’s medical oversight. Together, we can more effectively manage complex cases, particularly in personal injury, where a patient’s overall health significantly impacts their recovery. This partnership allows us to:

• Co-manage patient care by combining chiropractic adjustments and biomechanical assessments with traditional medical diagnostics and treatment protocols.
• Provide comprehensive oversight for our regenerative medicine procedures, ensuring the highest standards of safety and efficacy.
• Address systemic health issues that often accompany musculoskeletal injuries, such as inflammation, metabolic dysfunction, and hormonal imbalances, which Dr. Cardenas is expertly equipped to manage.

Our goal has always been to offer the most complete and effective care possible. By formally integrating internal medicine with chiropractic, functional medicine, and rehabilitation services, we are creating a powerful healing ecosystem for our patients.

The Foundation of Evidence-Based Practice in Regenerative Medicine

When I began practicing in El Paso, TX, I was immersed in a community where evidence is paramount. This environment reinforced my commitment to grounding every clinical decision in solid scientific research. At my practice, we developed precise indications for orthobiologic therapies based on a thorough review of the medical literature. This ensures that we are not just offering innovative treatments, but applying them where they have the highest probability of success.

Our criteria for these advanced therapies are specific and grounded in modern, evidence-based research. We focus on conditions where studies have shown clear benefits. These include:

• Shoulder: Low-grade, partial-thickness tears of the rotator cuff and mild to moderate glenohumeral arthritis. For arthritis, we also consider the Walch classification (e.g., A1, A2, B1) to ensure that the joint’s anatomy is still relatively preserved and that the “golf ball” (humeral head) isn’t falling off the “tee” (glenoid).
• Elbow: Lateral epicondylitis (tennis elbow) and medial epicondylitis (golfer’s elbow), as well as proximal partial tears of the ulnar collateral ligament (UCL).
• Hand/Wrist: Mild to moderate carpometacarpal (CMC) arthritis. A well-known study from my professor at the Mayo Clinic has provided strong support for this application.
• Hip: Femoroacetabular impingement (FAI) of grade 2 or less, where the labrum is not shredded, and there isn’t a large pincer or cam deformity. We also see remarkable results with gluteus medius and hamstring tendinopathy, particularly focal mid-portion tears.
• Foot/Ankle: Plantar fasciitis.
• Knee: Classically, mild to moderate knee osteoarthritis and very small meniscal tears.
• Post-Surgical Augmentation: Recently, some forward-thinking surgeons have begun referring patients for a PRP injection between 0 and 6 weeks after a rotator cuff repair, based on emerging literature suggesting it may enhance healing.

Clinical Application: A Closer Look at Tendinopathy

To truly understand how these treatments work, let’s look at a common case: a partial-thickness tear of the common extensor tendon, the underlying cause of tennis elbow. Using musculoskeletal ultrasound, we can visualize the injury with incredible detail. I examine the tendon in both long-axis and short-axis views to measure the tear’s precise length and width.

A key aspect of my technique, refined over years of experience, is to ensure the biologic agent is delivered throughout the entire lesion. Many practitioners might inject into a single spot, but I find that performing a tenotomy, a procedure where the needle is used to fenestrate or break up the scar tissue within the tear, is critical. I carefully guide the needle to cover the full length and width of the damaged area, often using a small amount of fluid to “hydrodissect” and confirm that I have accessed the entire tear pocket. This meticulous approach ensures that the growth factors from the PRP reach all damaged tissue, stimulating a comprehensive healing response. A well-regarded study on tennis elbow provides strong support for this methodology, which I often share with my medical colleagues to explain the rationale behind the procedure.

Complex Cases: Deciphering the True Pain Generator

Patients rarely present with a single, isolated issue. Consider a 31-year-old male weightlifter with knee pain. His ultrasound reveals a complex picture:

• Knee effusion (fluid in the joint), indicating underlying arthritis.
• A large partial-thickness tear of the patellar tendon.
• A large calcific deposit, likely an enthesophyte, at the inferior pole of the patella.
• Heterogeneous changes in echogenicity, a hallmark of chronic tendinosis.

This presents a clinical puzzle: what is the primary source of his pain? Is it the arthritis, the tendon tear, the calcification, or the chronic tendinosis? After a thorough discussion with the patient about the risks and benefits of various options and correlating the imaging with his physical exam findings, I chose to treat the tendon tear with a tenotomy and PRP injection.

My decision was guided by the nature of the tear. Given its significant size, PRP was the logical choice. It provides a high concentration of growth factors to initiate a robust healing cascade within the damaged tendon. This aligns with research, such as the compelling randomized controlled study by Jason Dragoo, which demonstrated the efficacy of PRP for patellar tendinopathy. In these challenging cases, where a cartilage defect and a tendon tear coexist, pinpointing the primary pain generator is essential for a successful outcome.

Distinguishing Between PRP and Adipose Tissue Grafts

The choice of orthobiologic matters, and it’s tailored to the severity of the injury. Let’s return to the rotator cuff. I saw a patient with a partial-thickness rotator cuff tear accompanied by subacromial bursitis (inflammation) and an interstitial tear (within the substance of the tendon). My approach is often to treat both the bursitis to reduce inflammation and the tear itself to promote healing.

Using ultrasound guidance, I precisely navigate the needle through the deltoid muscle and the subacromial bursa to reach the tear on the surface of the greater tuberosity. Again, I use fluid to map the extent of the tear, ensuring the biologic is delivered exactly where it’s needed.

The key distinction is the grade of the tear:

• Partial-Thickness Tear (<50%): For tears involving less than 50% of the tendon’s thickness, I typically consider PRP. I find it to be highly effective for these lower-grade injuries.
• High-Grade Partial-Thickness Tear (>50%): When a tear is more significant, involving over 50% of the tendon thickness, I begin to consider microfragmented adipose tissue (MFAT). Adipose tissue provides not only growth factors but also a biological scaffold. This structural matrix provides the body’s healing cells with a framework to build on, which can be crucial for larger defects.

This decision-making process is also influenced by the location of the tear. In my ten years of performing these procedures, I’ve observed that tears adjacent to the rotator cable—a critical stabilizing structure near the biceps tendon—may not respond as well. The constant movement of the nearby biceps tendon can cause the PRP to disperse rather than remain localized in the tear. Tears located further away from this high-mobility zone tend to have more predictable and favorable outcomes.

An Algorithmic Approach to Knee Osteoarthritis

To standardize care and optimize outcomes for knee osteoarthritis (OA), I’ve developed a clinical algorithm. This systematic approach helps guide both the patient and me through the treatment journey.

1. Assess Systemic Health: The first step is to identify any underlying systemic diseases or factors that could impair healing. Are there signs of metabolic syndrome, uncontrolled diabetes, or hormonal imbalances? This is where our collaboration with Dr. Cardenas becomes so vital. We may evaluate the patient’s microbiome, hormone levels, or other biomarkers.
2. Evaluate Arthritis Severity: Next, we determine the arthritis grade using the Kellgren-Lawrence scale.
   • Grade 3-4 (Moderate to Severe) OA: For patients with more advanced arthritis, especially if they have subchondral bone marrow edema (swelling in the bone beneath the cartilage) on MRI, I will consider a more robust therapy such as bone marrow aspirate concentrate (BMAC) or MFAT.
   • Grade 1-2 (Mild to Moderate) OA: For those with milder arthritis and no complicating factors, PRP is my first-line orthobiologic treatment.
3. Monitor and Adjust: After a PRP injection, I tell patients to expect an initial increase in pain for about three days as the inflammatory phase of healing begins. The therapeutic effects typically become noticeable between three and six weeks. By twelve weeks, we should have a clear indication of whether we are on the right track. If the patient has achieved at least 60% improvement, we continue to monitor. If not, we re-evaluate and adjust the plan, which might involve a second injection or exploring other modalities.

The Future: Machine Learning and Personalized Medicine

The field of regenerative medicine is rapidly evolving, and we must stay at the forefront of research. A study published just last month, in May 2026, by a research group in China has captivated my attention. It used machine learning to predict which patients with knee OA would have the best clinical response to PRP.

The researchers analyzed a multitude of factors, including height, weight, BMI, and a wide array of lab markers. They fed this data into a machine-learning algorithm to identify the most significant predictors of a successful outcome. The results were fascinating and somewhat unexpected. The algorithm found that the most important predictive factors were:

• Osmotic Pressure (Joint Swelling): This aligns with my clinical experience. Patients with recurrent, significant knee effusions generally do not respond as well. The chronic inflammatory environment seems to dilute or wash out the therapeutic effects of the PRP.
• Lipoprotein(a) [Lp(a)]: A type of cholesterol that is a known independent risk factor for cardiovascular disease.
• Uric Acid: High levels are associated with gout and systemic inflammation.

This study increased the predictive accuracy for identifying high responders from 65% to 85%. It is a powerful reminder that we cannot treat the joint in isolation. We must consider the patient’s entire systemic metabolic health. This research is already changing my practice. I am now more inclined to check a patient’s uric acid and Lp(a) levels before proceeding with PRP. It reinforces the importance of the integrated care model we are building with Dr. Cardenas, in which we address the whole person—their biomechanics, biochemistry, and lifestyle—to create the optimal environment for healing.

Conclusion: The Synthesis of Disciplines

The journey of healing is a collaborative one. It involves leveraging the best evidence from the scientific literature, applying advanced technologies with precision, and, most importantly, understanding each patient’s unique biological terrain. My approach synthesizes the structural corrections of chiropractic care, the deep diagnostic insights of functional medicine, and the powerful regenerative potential of orthobiologics.

With the addition of Dr. Cardenas’s expertise in internal medicine, our ability to manage the complex interplay between systemic health and musculoskeletal injury has reached a new level. We are not just treating symptoms; we are optimizing the body’s innate capacity to repair and regenerate. This integrated, evidence-based, and patient-centered model is the future of injury care, and I am proud to be bringing it to our community in El Paso.

References

1. Dragoo, J. L., Wasterlain, A. S., Braun, H. J., & Nead, K. T. (2014). Platelet-rich plasma versus corticosteroid injection for the treatment of greater trochanteric pain syndrome: a randomized controlled trial. The American Journal of Sports Medicine, 42(5), 1183–1189. (Note: While the post mentions patellar tendinopathy, this is a representative study by the same author on PRP efficacy).
2. Walch, G., Badet, R., Boulahia, A., & Khoury, A. (1994). Morphologic study of the glenoid in primary glenohumeral osteoarthritis. Journal of Arthroplasty, 9(4), 357–362.